🇺🇸 FDA
Patent

US 12220415

WEE1 kinase inhibitors and methods of treating cancer using the same

granted A61KA61K31/495A61K31/519

Quick answer

US patent 12220415 (WEE1 kinase inhibitors and methods of treating cancer using the same) held by The Regents of the University of Colorado, a Body Corporate expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/495, A61K31/519, A61K31/635, A61K31/704